Summary
A BMJ editorial argues that drug regulatory decisions should show more clearly when licensing committees disagree about benefits, risks and evidentiary uncertainty. It highlights the European Medicines Agency’s formal process for recording dissent.
A BMJ editorial argues that drug-approval decisions should make committee disagreement more visible, particularly when regulators are weighing limited or uncertain evidence. Published on 21 September 2026, the editorial by Maximilian Siebert and Ariadna Tibau focuses on the value of recording dissent within licensing committees.
The authors describe marketing authorisation as a decision about whether a medicine can enter the market after assessment of its benefit-risk balance and supporting evidence. Regulators must consider clinical benefit, the robustness of the methods used to generate evidence, uncertainty in that evidence and the level of unmet medical need.
Why disagreement matters in approval decisions
The final regulatory decision is usually binary: a medicine receives authorisation or it does not. The committee reaching that decision, however, may not be unanimous. Experts can interpret the same evidence differently or place different weight on potential benefits, risks and remaining uncertainties.
When the final decision records only the outcome, the reasoning of a minority may be less visible. The editorial argues that documenting disagreement would give healthcare professionals, researchers and the public a clearer view of the evidence and the judgments behind an approval.
This issue is especially relevant when decisions rely on expedited regulatory pathways, surrogate endpoints or a limited evidence base. A surrogate endpoint is an intermediate measure used in place of a direct clinical outcome, such as how a patient feels, functions or survives. Such evidence can be useful for decisions, but its interpretation may involve important uncertainty.
How the EMA records dissent
The editorial uses the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, as an example. Applications are assessed by the committee, which seeks consensus where possible. If consensus cannot be reached, the decision is made by an absolute majority of voting members.
A CHMP member who disagrees with the majority can formally record that disagreement and the reasons for it in a written “divergent opinion”. This creates a mechanism for preserving minority reasoning alongside the committee’s final decision.
The editorial’s proposal
Siebert and Tibau argue that divergent opinions deserve more attention as part of transparent regulatory decision-making. Their central point is not that disagreement invalidates an approval. Rather, recording the reasons for disagreement can show where experts differ over the strength of evidence, the balance of benefits and risks, or the degree of uncertainty accepted at the time of licensing.
The article is an editorial argument, not a report of a new clinical study or a newly announced regulatory rule. It presents clearer documentation of dissent as a way to improve understanding of how medicines are assessed when the available evidence requires substantial expert judgment.